Physician profile
Nadeem Jamil
NPI 1649234576
$5,551.20
in general payments reported to CMS, 2019-2025
48 companies · $943 in 2025
The $943 reported for 2025 was more than what 88% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,054 · 2020: $219 · 2021: $768 · 2022: $657 · 2023: $950 · 2024: $960 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,853.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $832.74 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $564.86 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $558.62 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $308.15 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $295.14 | 2020-2025 | Nexletol |
| Biotronik INC. | $247.67 | 2019 | |
| Abbott Laboratories | $205.32 | 2019-2024 | Freestyle Libre 3 |
| Pfizer INC. | $200.37 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $186.97 | 2021-2023 | |
| Abbvie INC. | $186.24 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.28 | 2021-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.22 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $133.09 | 2019-2022 | |
| Amgen INC. | $119.36 | 2019-2025 | Krystexxa |
| Ablative Solutions, INC. | $114.50 | 2019 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadeem Jamil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.